Drug Profile
Research programme: oncology companion diagnostics - AstraZeneca/Illumina
Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator AstraZeneca; Illumina
- Developer AstraZeneca
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Cancer(Diagnosis) in United Kingdom
- 21 Aug 2014 Early research in Cancer (Diagnosis) in United Kingdom (unspecified route)